Abstract

We attempt to study the efficacy and adverse reactions of carboplatin, nab-paclitaxel regimen combined with atezolizumab in non-small cell lung cancer treatment. We randomly selected 120 non-small cell lung cancer patients who received therapy in our hospital from January 2019 to December 2021 and divided them into two groups, 60 cases respectively. Treated control group with carboplatin and paclitaxel combined with pembrolizumab, while observation group with carboplatin and albumin paclitaxel combined with pembrolizumab. Compared both groups on the efficacy, incidence of adverse reactions, levels of peripheral blood lymphocyte subsets and serum tumor markers. After treatment, observation group possessed higher objective remission rate and disease control rate than control group (p<0.05); observation group had lower adverse reactions rate during the treatment period than control group (p<0.05); observation group had higher cluster of differentiation 3⁺, cluster of differentiation 4⁺ and cluster of differentiation 4⁺/cluster of differentiation 8⁺ values than control group, but it possessed lower cluster of differentiation 8⁺ values than control group (p<0.05). Observation group had lower cytokeratin 19 fragment antigen 21-l, squamous cell carcinoma antigen, carbohydrate antigen 125 and carcinoembryonic antigen levels than control group (p<0.05). Carboplatin, nab-paclitaxel regimen combined with atezolizumab in treating non-small cell lung cancer patients can effectively alleviate and control their disease, reduce the risk of adverse reactions during the treatment process and improve the body’s immune function, which is worthy of promotion.